当代两阶段治疗假体周围髋关节感染:基于循证标准化方案效果优异
总体治疗成功率为95.7%(44/46),平均无感染生存期67.2个月。作者认为对两阶段治疗的批评及支持单阶段的论据可能被夸大,在更确切数据出现前不鼓励推广单阶段方案。
要点
- 标准化两阶段方案治疗假体周围髋关节感染总体成功率达95.7%。
- 早期和急性血源性感染成功率为100%,慢性感染在宿主条件良好者亦为100%。
- 宿主严重受损的慢性感染成功率降至83.3%(5/6)。
核心结论
- 当代标准化两阶段治疗假体周围髋关节感染可获得优异的治疗成功率。
- 对两阶段治疗的批评及支持单阶段治疗的论据可能被夸大,在更确切数据出现前不鼓励推广单阶段方案。
研究设计与样本
- 标准化方案包括植入物切除、彻底外科清创、抗生素间隔物、6周静脉抗生素、2周药物假期及再植入前实验室评估。
- 再植入后预防性静脉抗生素至出院,口服抗生素至少7天直至术中培养最终结果。
- 治疗成功按Delphi-based国际多学科共识定义。
主要发现
- 总体治疗成功率为95.7%(44/46例),平均无感染生存期为67.2个月(范围23.8-106.4个月)。
- 早期和急性血源性感染无论宿主类型成功率均为100%,慢性感染在宿主未受损者成功率100%。
- 慢性感染在宿主受损者成功率为95%(19/20),在宿主严重受损者成功率为83.3%(5/6)。
- 初次髋约4%、翻修髋约20%在初始切除后需重复清创和间隔物更换。
- 无患者因治疗死亡。
关键数值与推荐
- 治疗成功按Delphi-based国际多学科共识定义。
- 标准化方案包括6周静脉抗生素、2周药物假期及再植入前实验室评估感染根除。
- 再植入后口服抗生素至少7天直至术中培养最终结果。
临床怎么用
- 对假体周围髋关节感染可遵循标准化两阶段方案:彻底清创、抗生素间隔物、6周静脉抗生素、2周药物假期、再植入前实验室评估。
- 再植入后应继续预防性静脉抗生素至出院,并口服抗生素至少7天直至术中培养最终结果。
- 在更确切数据出现前,不应不加批判地推广单阶段治疗方案。
局限性
- 回顾性研究设计。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study quantified the effectiveness of contemporary and evidence-based standardized 2-stage treatment for periprosthetic hip infection. Findings illustrate potential limitations of criticisms of 2-stage protocols and potential consequences of adopting single-stage protocols before definitive data are available. METHODS: Fifty-four consecutive hips treated with 2-stage resection and reimplantation were retrospectively reviewed. Standardized protocols were adhered to including implant resection, meticulous surgical debridement, antibiotic spacer, 6-week intravenous antibiotics, a 2-week drug holiday, and laboratory assessment of infection eradication before reimplantation. After reimplantation, patients were placed on prophylactic intravenous antibiotics until discharge and discharged on oral antibiotics for a minimum of 7 days until intraoperative cultures were final. Successful treatment was defined per Delphi-based International Multidisciplinary Consensus. RESULTS: The overall treatment success rate was 95.7% (44 of 46 cases) with mean infection-free survivorship of 67.2 (range, 23.8-106.4) months. Success rates were 100% for early and acute hematogenous infections regardless of host type and 100% for chronic infections in uncompromised hosts. 95% (19/20) of chronic infections in compromised hosts and 83.3% (5/6) of chronic infections in significantly compromised hosts were successfully treated. About 4% of primary hips and 20% of revision hips required repeat debridement and spacer exchange after initial resection. No patients died because of treatment. CONCLUSION: Details from this consecutive series of patients undergoing 2-stage treatment for hip infection suggest that some criticisms of 2-stage treatment as well as some arguments in support of single-stage treatment may be overstated. Promotion and uncritical adoption of single-stage treatment protocols are discouraged until further and more definitive data exist.
引用
- Wichern EM, Zielinski MR, Ziemba-Davis M, et al. Contemporary 2-Stage Treatment of Periprosthetic Hip Infection with Evidence-Based Standardized Protocols Yields Excellent Results: Caveats and Recommendations. J Arthroplasty. 2020. PMID: 32540305. doi:10.1016/j.arth.2020.05.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。